Prime Medicine, Inc. (PRME) News
Follow Prime Medicine, Inc. (PRME) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 22 public stories across 14 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Weekly Recap: PM647 IND clearance and Chardan keeps $7 Buy on PRME
Prime Medicine, Inc. (NASDAQ:PRME) jumped about 13% after FDA IND clearance for PM647, clearing the way for U.S. first—in—human Phase 1/2 AATD trials with initial data expected in 2027, while Chardan Capital kept a Buy r
REGULATION | Sep 28, 2026, 11:05 AM UTC
L
Prime Medicine Price Target Maintained With a $7.00/Share by Chardan Capital
Ratings actions from Benzinga
NEWS | Sep 25, 2026, 12:20 PM UTC
L
Prime Medicine Announces U.S. FDA Clearance Of Investigational New Drug Application For Pm647 In Alpha-1 Antitrypsin Deficiency
Prime Medicine, Inc. NASDAQ:PRME
REGULATION | Sep 24, 2026, 10:06 PM UTC
L
Prime Drink Group Corp. (PRME) Extends Filing Deadline; MCTO Remains
Prime Drink Group says its MCTO remains in effect as the BCSC extended the deadline to file FY2026 annual financials to on or before Sept. 28, 2026. CEO and CFO remain restricted from trading until filings are made and M
NEWS | Sep 24, 2026, 09:34 PM UTC
L
Prime Drink Group Provides Bi-Weekly MCTO Status Report
MONTREAL, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. CSE:PRME(“Prime” or the “Company”) announces that further to its news releases dated July 30, August 14, August 27 and September 10, 2026, the Company
REGULATION | Sep 24, 2026, 09:33 PM UTC
L
Prime Medicine Shares Jump on FDA Clearance for Investigational New Drug Application
By Elias SchisgallShares of Prime Medicine jumped after the biotechnology company said the Food and Drug Administration cleared its investigational new drug application for PM647 to treat the genetic disease Alpha-1 Anti
REGULATION | Sep 24, 2026, 09:09 PM UTC
L
CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?
Gene-editing stocks sold off on Wednesday after Anthropic said its Claude model had flagged a phage enzyme system that shares a few design traits with CRISPR — the platform behind approved and experimental DNA-editing me
EQUITY | Sep 23, 2026, 09:49 PM UTC
L
PRME: Prime Editing advances versatile gene therapies with strong clinical and financial momentum
Prime Editing offers broad, precise, and safe genome editing, with clinical progress in CGD, Wilson disease, and Alpha-1 programs. Regulatory flexibility and platform synergies support rapid expansion, while a strong cas
NEWS | Sep 15, 2026, 03:16 PM UTC
L
PRME: Prime Editing enables versatile, safe gene editing with key clinical and regulatory milestones ahead
Prime Editing technology offers broad, precise, and safe genome editing, with lead programs advancing in Wilson disease, Alpha-1, and CGD. The LNP platform enables rapid expansion across indications, and regulatory flexi
NEWS | Sep 15, 2026, 02:44 PM UTC
L
Prime Drink Group closes first tranche of non-brokered private placement for $1,349,200
Prime Drink Group Corp. announced the first closing of its previously announced non-brokered private placement unit offering. The offering raised gross proceeds of $1,349,200.
EQUITY | Sep 10, 2026, 11:32 AM UTC
L
PRME - Prime Medicine to Participate in Upcoming Investor Conferences
PRME - Prime Medicine to Participate in Upcoming Investor Conferences
EQUITY | Sep 03, 2026, 12:00 PM UTC
L
Prime Drink Group provides bi-weekly MCTO status report
Prime Drink Group provided a bi-weekly MCTO status report.
EQUITY | Aug 27, 2026, 09:37 PM UTC
L
Prime Drink Group signs strategic partnership to expand Beach Day
Prime Drink Group entered a strategic partnership with Groupe Geloso to accelerate expansion of Beach Day Every Day across Canada, the U.S. and Europe.
EQUITY | Aug 27, 2026, 11:37 AM UTC
M
Prime Drink Group executes binding LOI for Beach Day acquisition
Prime Drink Group announced it has executed a binding letter of intent to acquire Beach Day Every Day and enter concurrent financing.
EQUITY | Aug 26, 2026, 11:37 AM UTC
M
Prime to acquire all issued shares of PCI
Prime will acquire all issued and outstanding shares of PCI, per TradingView News.
EQUITY | Aug 26, 2026, 11:32 AM UTC
L
TEM shares now up over 23% PRME +17% RXRX +11% and DNA about 16%, extending gains all day in Precision Medicine, or Biomedical/genetics sub
TEM shares now up over 23% PRME +17% RXRX +11% and DNA about 16%, extending gains all day in Precision Medicine, or Biomedical/genetics sub-areas which have all rallied behind the MRNA/MRK news today
EQUITY | Aug 19, 2026, 07:34 PM UTC
L
BMO, Wedbush, Wolfe and RBC issue stock initiations
BMO, Wedbush, Wolfe, RBC and Cantor initiate coverage with ratings changes on AKTS, ALNY, ASND, BCAX, BMRN, CATX, PRME, AFL, AGMB, COR and MCK.
EQUITY | Aug 19, 2026, 11:09 AM UTC
L
PRME - Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates
PRME - Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates
EARNINGS | Aug 06, 2026, 12:00 PM UTC
L
PRME prime Medicine announces U.S. FDA clearance of investigational new drug application for pm577a in h1069q-mutated Wilson disease
PRME prime Medicine announces U.S. FDA clearance of investigational new drug application for pm577a in h1069q-mutated Wilson disease
REGULATION | Jul 23, 2026, 08:05 PM UTC
M
HC Wainwright & Co. Upgrades Prime Medicine to Buy, Announces $8 Price Target
HC Wainwright & Co. analyst Arthur He upgrades Prime Medicine (NASDAQ: PRME ) from Neutral to Buy and announces $8 price target.
EQUITY | Jun 29, 2026, 10:13 AM UTC
H
PRME: FDA Grants Designation
Prime Medicine says FDA grants regenerative medicine advanced therapy designation to PM359 for treatment of p47phox-deficient CGD
EQUITY | Jun 22, 2026, 12:15 PM UTC
H
PRME Receives FDA RMAT Designation
Prime Medicine receives U.S. FDA Regenerative Medicine Advanced Therapy designation for PM359 to treat Chronic Granulomatous Disease
EQUITY | Jun 22, 2026, 12:01 PM UTC